Daiichi, J&J Unit Continue Fight For Levaquin Patent

Law360, New York (October 19, 2006, 12:00 AM EDT) -- After a series of courtroom victories over anti-infective drug Levaquin, Japanese drug maker Daiichi Pharmaceutical Co. and a Johnson & Johnson subsidiary have filed a lawsuit to fight another effort to market a generic version of the drug.

The lawsuit, filed Tuesday in the U.S. District Court for the District of New Jersey, alleges that India-based Lupin Ltd. and its subsidiary, Lupin Pharmaceuticals, are infringing on the patent held by Daiichi and licensed to Johnson & Johnson and its subsidiary Ortho-McNeil Pharmaceutical Inc.

Daiichi has held...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.